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Over the last decade, diagnostic options and introduction of novel treatments have expanded the armamentarium in the
management of malignant glioma. Combined chemoradiotherapy has become the standard of care in glioblastoma up
to the age of 70 years, while treatment in elderly patients or with lower grade glioma is less well deﬁned. Molecular
markers deﬁne different disease subtypes and allow for adapted treatment selection. This review focuses on simple
questions arising in the daily management of patients.
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introduction
The management of gliomas has changed in the last decade. In
2005, combined modality therapy with temozolomide (TMZ)
and radiation therapy has become the standard ﬁrst-line
treatment in glioblastoma (GBM). Numerous new agents,
including targeted and antiangiogenic agents are under
investigation for the treatment of newly diagnosed or recurrent
glioma. Molecular markers, such as isocitrate dehydrogenase
1 (IDH1) in low-grade gliomas, loss of heterozygoty 1p/19q
(LOH 1p/19q) in oligodendrogliomas or promoter methylation
status of the methyl-guanine methyl transferase (MGMT) gene
may help identifying distinct subtypes of gliomas and may help
predict response to treatment and outcome. We, here, aim on
answering 10 practical questions in the medical management of
malignant glioma.
questions
1. should the temozolomide (TMZ) maintenance be
prolonged for patients with GBM?
In the pilot and in the randomized European Organization for
Research and Treatment of Cancer/National Cancer Institute
of Canada (EORTC/NCIC) landmark phase III trial, the 6-
month duration of the adjuvant/maintenance TMZ
chemotherapy had been chosen arbitrarily on the basis of
experience with adjuvant chemotherapy in colon and breast
cancer [1]. Given the good tolerance of TMZ and the fact that
in GBM, residual macroscopic disease often remains after
surgery, some neurooncologists extend the duration of
maintenance therapy to 12 months and longer (e.g. for as long
as tumor regression is visible on serial magnetic resonance
imagings or until tumor progression). Continued tumor
regression on imaging has also been observed after
discontinuation of therapy. There are no data suggesting an
improved outcome with prolonged maintenance
chemotherapy. The recently completed Radiation Therapy
Oncology Group (RTOG) 0525/North Central Cancer
Treatment Group (NCCTG)/European Organization for the
Research and Treatment of Cancer (EORTC) Intergroup trial
investigated intensiﬁed adjuvant/maintenance therapy.
Although in the experimental arm twice the dose intensity of
TMZ was delivered, no improvement in any of the outcome
parameters was observed. This trial allowed for prolonged
administration of adjuvant therapy in responding patients for
up to 12 months, a practice widely adopted in the United
States. However, no difference in outcome was detected
between the American and the European patients. Despite
treatment intensiﬁcation and more aggressive salvage
treatment, the median survival from trial registration (soon
after surgery) is only 16 months, with a 2-year survival rate of
28%, comparable to the results of the EORTC/National Cancer
Institute of Canada (NCIC) trial conducted 6 years earlier.
A number of other reasons speak against prolongation of
treatment duration. As with all alkylating agents, there is a risk
of development of secondary leukemia and myelodysplastic
syndromes. Even though TMZ is usually well tolerated, it is
associated with mild-to-moderate asthenia and fatigue,
symptoms often appreciated only when treatment has been
discontinued. A treatment pause may result in the improved
quality of life. Chronic chemotherapy leads to cumulative bone
marrow toxicity, thus limiting treatment options for salvage
chemotherapy. Chemotherapy resistance may also be decreased
with intermittent treatment.
2. should all GBM patients be tested for MGMT?
The randomized EORTC/NCIC phase III trial established
concomitant and adjuvant (maintenance) TMZ chemotherapy
with and after irradiation (TMZ/RT→TMZ) as the standard of
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care. Median survival was improved from 12.1 months with
initial RT alone, to 14.6 months when TMZ was added.
Signiﬁcantly, the 2-year survival rates increased from 10% to
27%. The silencing of DNA repair protein MGMT has been
associated with beneﬁt from alkylating agent chemotherapy, as
this enzyme repairs the toxic injuries inﬂicted to tumor cells by
alkylating chemotherapeutic agents [2]. This hypothesis was
conﬁrmed retrospectively in the randomized trial. The beneﬁt
of the addition of TMZ chemotherapy was shown to be mainly
restricted to patients whose tumors have a methylated MGMT
gene promoter, and have, therefore, a limited capacity to repair
some of the alkylating agent chemotherapy-induced DNA
damages [3, 4]. The recently reported RTOG0525/NCCTG/
EORTC Intergroup study prospectively validated MGMT gene
promoter testing and its association with outcome. This study
included mandatory central MGMT methylation status
determination, as stratiﬁcation factor before randomization.
It is reasonable to question whether all GBM patients should
be tested for the methylation status of the promoter region of
the MGMT gene. However, information on a predictive marker
is useful only if it will permit to adapt the treatment strategy to
improve the outcome and/or the quality of life in patients. In
the RTOG study, dose intensiﬁcation failed to overcome TMZ-
mediated resistance or to further improve outcome in patients
with a methylated MGMT promoter. Outside of clinical trials,
there are currently no adequate alternative treatment strategies
for patients without methylated MGMT promoter regions.
Therefore, short of any promising alternative treatment, the
practical value of MGMT testing remains largely prognostic
and, thus, we do not assess the MGMT status routinely.
Nevertheless, there are a number of situations, where
knowledge of the MGMT status may be of practical use and
inﬂuence patient management:
• In patients with a borderline performance status, where in
the absence of an expected major response to chemotherapy,
management may be limited to supportive care only. In an
elderly population, it was shown that active treatment with
TMZ might offer signiﬁcant chances of a tumor response
and improvement in performance and cognitive status,
allowing some independence and enhancement of quality of
life. And response was strongly correlated with the presence
of MGMT promoter methylation in the tumor [5]. The
speciﬁc situation of elderly patients will be discussed below.
• When in doubt of whether observed radiological progression
is likely to be pseudoprogression. Here, patients with
methylated MGMT are more likely to develop tumor
necrosis and associated disruption of the blood–brain
barrier, leading to increased contrast enhancement that
could be falsely considered as tumor progression [6].
• When in doubt whether alkylating agent chemotherapy
should be continued or reintroduced, the presence of MGMT
promoter methylation may be a reason to favor alkylating
agent chemotherapy.
3. what is the role of IDH1 in the management of
glioma?
Isocitrate dehydrogenases are a group of enzymes involved in
monocarbon metabolism, which catalyzes the conversion of
isocitrate to α-ketoglutarate. Mutations in IDH genes,
particularly IDH1R132MUT have been shown to be characteristic
of low-grade gliomas and to represent one of the earliest
mutations in gliomas and may initiate glioma formation. They
have been identiﬁed in over 70% of grade II gliomas and ∼50%
of grade III lesions [7–9]. The overall rare secondary GBMs
also have a high propensity to harbor IDH mutations. The
patients whose GBM contained an IDH1 mutation showed a
longer survival than those with wild-type IDH1. Actually these
patients showed also better survival than patients with grade
III gliomas that did not harbor the IDH1 mutation [10]. In
low-grade gliomas, the prognostic or predictive role of IDH1
mutations remains however controversial in grade II gliomas
[11]. IDH mutation status can be analyzed easily and
reproducibly by simple PCR and sequence analysis. For the
more frequent IDH1 mutation, a monoclonal antibody is
available, allowing demonstration of the presence of the
mutation by immunohistochemistry [12] (Figure 1).
In clinical practice, IDH1 is not only a prognostic marker for
high-grade gliomas. IDH1 mutations may also be used as a
diagnostic marker to identify diffuse tumor inﬁltration of
astrocytoma or oligodendroglioma and distinguish diffuse
tumor inﬁltration from reactive astrocytosis (IDH1 wild type).
The presence of IDH1 mutation may help distinguish WHO
grade I pilocytic astrocytoma (no IDH1 mutations) from
diffuse astrocytomas [13]. Similarly, ependymomas do not
harbor mutant IDH1 [14, 15]. Finally, mutant IDH1 may help
the pathologist distinguish oligodendrogliomas from other
glioneuronal tumors with clear-cell morphology.
4. how to treat elderly patients with GBM?
In the randomized EORTC/NCIC (landmark phase III trial,
only patients up to the age of 70 years were included (Table 1).
Age is a major prognostic factor for poorer outcome, and it
was not felt appropriate to propose a combined modality and
lengthy treatment to patients with a short life expectancy [16].
Consistently, outcome in patients over the age of 50 years was
worse than for younger patients in the EORTC/NCIC trial.
Figure 1. Expression of mutated IDH1 protein in glioblastoma.
Immunohistochemistry using a mouse monoclonal antibody targeting the
IDH1 R132H mutation.
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Nevertheless, the hazard ratio in patients between 60 and 65
years [0.64 (0.43–0.94), P = 0.02)] and 65–70 years [0.78 (0.50–
1.24), P = 0.29] favored combined modality therapy in these
subgroups. In a general nonprotocol population, the median
age of GBM patients is >65 years (compared with 50–55 years
in clinical trials), and the study results cannot be simply
extrapolated to the elderly. A number of factors may explain
the inferior outcome in elderly GBM patients: comorbidities
and a frail general condition, and consequently inferior
tolerance to combined modality therapy, or a less aggressive
attitude to active therapy by both physicians and patients alike.
Palliative treatments extending over several weeks may not be
justiﬁed in patients with a short life expectancy. A small
randomized Canadian trial on 100 subjects showed that for
elderly patients with a Karnofsky performance status (KPS)
between 60 and 80, hypofractionated RT to a total dose of 40
Gy in 15 fractions given over 3 weeks resulted in similar overall
survival (OS) than the standard 60 Gy given in 30 fractions
over 6 weeks with a median OS of 5.6 months in both groups
[17]. The results of two randomized phase III trials were
recently published [18, 19]. The Nordic trial randomized
patients into receiving either (i) TMZ alone (150 mg/m2/days
1–5 every 28 days for up to 12 cycles versus (ii) RT to 60 Gy in
30 fractions of 2 Gy over 6 weeks versus (iii) RT to 34 Gy in
10 fraction over 2 weeks. This trial enrolled 342 patients over
the age of 60 years (median 70 years) and with a KPS of at
least 60. There were no signiﬁcant differences in OS when all
patients were considered (intent to treat); median OS was 8.3,
Table 1: Randomized multicenter trials for high grade gliomas.
Name of trial Indication Phase Primary
end point
Design Number of
patients
Outcome Comments
Median
PFS
(months)
Median OS
(months)
EORTC
26981 [1]
First-line GBM III OS Arm 1: RT60 Gy 260 5.0 12.1 Patients: 18–70 years old/PFS:
HR: 0.54 (95% CI 0.45–
0.64), P < 0.001/OS: HR:
0.62 (95% CI 0.51–0.75),
P < 0.001
Arm 2: RT60 Gy/
TMZ75 mg/m2/day
⇒ TMZ150-200 mg/
m2/days 1–5
260 6.9 14.6
RTOG0525 First-line GBM III OS Arm 1: RT60 Gy/
TMZ75 mg/m2/day
⇒ TMZ150-200 mg/
m2/days 1–5 RT
versus
411 5.5 16.6 Patients: 18–70 years old/data
from ASCO 2011/OS: HR:
1.03 (0.88–1.20), P = 0.63/
PFS: HR: 0.87 (0.75–1.00),
P = 0.06
Arm 2: 60 Gy/TMZ75
mg/m2/day ⇒
TMZ100 mg/m2/days
1–21
420 6.7 14.9
Nordic trial First-line GBM in
elderly
III OS Arm 1: RT60 Gy/30 f
(6 weeks)
100 NA 6.0 Data from ASCO 2011
Arm 2: RT34 Gy/10 f
(2 weeks)
123 NA 7.5
Arm 3: TMZ150 mg/
m2/days 1–5
119 NA 8.3
NOA-08 First-line GBM in
elderly
III OS Arm 1: RT 60 Gy 179 NA 9.6 Data from ASCO 2011/OS:
HR: 1.09 (0.84–1.42)Arm 2: TMZ100 mg/
m2/days 1–7 every 14
days
194 NA 8.6
NOA-04 [44] First-line grade III
gliomas
III TTF Arm 1: RT60 Gy ⇒
PCV or TMZ at PD
139 30.6 (TTF) NR TTF: HR: 1.2 (95% CI
0.8–1.8), P = 0.28
Arm 2: PCV or TMZ
⇒ RT at PD
135 31.9 (TTF) NR
EORTC
26951 [42]
First-line grade III
oligodendroglioma
III OS Arm 1: RT 45 Gy 183 13 30.6 OS: HR: 0.85 (95% CI
0.53–0.87), P = 0.23/PFS:
HR: 0.68 (95% CI 0.53–
0.87), P = 0.018
Arm 2: RT 45 Gy ⇒
PCV
185 23 40.3
RTOG9402
[43]
First-line grade III
oligodendroglioma
III OS Arm 1: PCV/RT 147 NR NR OS: HR: 0.9 (0.66–1.24),
P = 0.26/PFS: HR: 0.69
(95% CI 0.52–0.91),
P = 0.04
Arm 2: RT 142 31.2 79.2
95% CI, 95% conﬁdence interval; f, fraction; Gy, gray; HR, hazard ratio; OS, overall survival; PCV, procarbazine, lomustine, vincristine; PFS, progression free
survival; RT, radiotherapy; TMZ, temozolomide; TTF, time-to-treatment failure at 2nd progression; NA, not available; NR, not reached.
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6.0 and 7.5 months, for TMZ, RT60 and RT34, respectively.
The difference between patients receiving 34 Gy or TMZ was
not statistically signiﬁcant. However, elderly patients older than
70 years (n = 123) derived signiﬁcantly more beneﬁt from
receiving TMZ alone than 60 Gy of RT. The high dropout rate
and particularly poor outcome in patients treated with
standard fractionated 6-weeks course of radiotherapy suggests
that this strategy may be too burdensome for elderly patients.
On multivariate analysis, younger age (60–70 versus 70+),
better performance status, more extensive resection and steroid
independence could be identiﬁed as independent prognostic
factors for a better outcome. The German Neuro-Onkologische
Arbeitsgruppe (NOA)-08 phase III trial included patients with
both GBM and anaplastic astrocytoma aged over 65 years and
a KPS of at least 60. Patients were randomized to receive either
standard fractionated RT (54–60 Gy in fractions of 1.8–2 Gy
over 6 weeks) versus dose-dense TMZ (100 mg/m2/day 1 week
on/1 week off ). There was no signiﬁcant difference in OS
between both groups. Interestingly, in both studies, patients
with a methylated MGMT promoter derived signiﬁcantly more
beneﬁt from receiving TMZ. The NCIC and EORTC are
conducting a joint phase III trial evaluating a short course of
RT alone administered over 3 weeks versus the combination
of the same course of RT combined with TMZ in patients
over 65 years of age that are not candidates to receive standard
RT/TMZ→TMZ (clinicaltrials.gov: NCT00482677).
We conclude that, in daily practice, treatment of elderly
should be tailored individually. In elderly patients with a good
performance status and few comorbidities, we often
recommend the standard TMZ/RT→TMZ protocol [1]. In the
patients older than 70 years, we usually administer
hypofractionated RT and concomitant TMZ. If the patient has
a KPS below 70–80, and MGMT promoter region is
methylated, we recommend treatment with TMZ alone [5]. If
the tumor is unmethylated, hypofractionated RT alone or
exclusive supportive care should be considered.
5. what is the value of alternative dose-dense
temozolomide dosing regimens?
TMZ (Temodal®, Temodar®, Merck & Co., Whitehouse Station,
NJ) was initially approved for recurrent glioma with a 5
consecutive days dosing scheme every 28 days at a dose of
150–200 mg/m2. This regimen was selected based on
preclinical data. Subsequently, alternative continuous and
intensive dose-dense intermittent dosing regimens were tested
in phase I clinical trials [20, 21]. These dosing schedules
allowed for increasing the dose intensity, and at maximally
tolerated doses a doubling of the cumulative monthly dose was
achieved, without increase in severe toxicity. Continuous
exposure to TMZ will deplete the DNA repair protein MGMT
in peripheral blood mononuclear cells [21]. It was postulated
that this may be a way to overcome MGMT medicated
resistance by exhausting the cellular repair protein reservoir
[21]. Furthermore, continuous ‘metronomic’ exposure to low
doses of TMZ might be toxic to endothelial cells and exhibit
antiangiogenic properties. A number of uncontrolled (!) phase
II studies then suggested that intensifying the exposure to TMZ
may indeed increase the response rate, progression free survival
and OS [22–26]. Based on these assumptions, the RTOG0525/
Intergroup randomized phase III trial compared standard dose
adjuvant TMZ (150–200 mg/m2 daily for 5 days in 28-day
cycles) with a dose-dense regimen (75–100 mg/m2 daily for 21
days in 28-day cycles). No difference in any of the outcome
parameters was shown, and disappointingly, the treatment
intensiﬁcation did neither allow to overcoming resistance to
TMZ in patients with unmethylated tumors, nor to improving
further the outcome in patients beneﬁtting from the addition
of TMZ. Similarly, a British trial comparing dose
intensiﬁcation (21/28 days versus 5/28 days) in chemonaive
glioma patients with recurrent disease also failed to
demonstrate a beneﬁt for the dose-dense regimen. Actually,
survival was slightly, but not signiﬁcantly improved with the
daily × ﬁve standard regimen [27]. An ongoing trial (Director
Study, PI: Michael Weller, clinicaltrials.gov: NCT00941460) is
comparing the week-on/week-off regime with the 21/28 days
regimen in GBM patients who recurred after prior TMZ/
RT→TMZ standard therapy. A special focus will be on
molecular markers and predictive factors. The trial aims for
histological conﬁrmation of the recurrence and determination
of MGMT in the majority of patients.
The currently available data does not support the common
practice of TMZ dose intensiﬁcation at recurrence, but such a
strategy has also not been formally disproven.
6. should bevacizumab be added to the standard
ﬁrst-line treatment of glioblastoma?
Bevacizumab (BEV, Avastin®, Roche, Basel, Switzerland), a
humanized monoclonal antibody directed against the vascular
endothelial growth factor, has received provisional approval by
the US Food and Drug Administration for recurrent GBM,
while this indication was rejected by the European Medicines
Agency due to the lack of controlled data [28, 29]. Given the
fact that BEV can easily be combined with cytotoxic
chemotherapy, introduction of this antiangiogenic therapy in
the upfront setting has gained interest. Feasibility and safety
have been shown in a small phase I trial [30]. Two phase II
studies evaluated the addition of BEV (10 mg/kg every other
week) to standard TMZ/RT starting within 3–6 weeks after
surgery. After completion of TMZ/RT, patients resumed TMZ
for 5 days every 4 weeks while continuing biweekly BEV. This
combination treatment was well tolerated with toxicity similar
to standard TMZ/RT alone. In their single institution
experience, Narayana et al. reported on 51 patients with a
promising progression-free survival (PFS) of 13 months and
OS of 23 months [conﬁdence intervals (CI) not reported, study
immature at the time of the report] [31]. An analysis of
patients treated at Kaiser Permanente and University of
California in Los Angeles (UCLA), reported an OS of 16.9
months (95% CI 16.1–23.3). Although this compares favorably
to the results of the EORTC-NCIC trial (14.6 months, 95% CI
13.2–16.8), the outcome was not different from a series of
patients treated at the same institutions with standard ﬁrst-line
treatment TMZ/RT→TMZ, and BEV administered at the ﬁrst
recurrence (median survival 21.1 months (95% CI 18.9–25.2)
[32]. Two similar randomized phase III trials have been
launched. In RTOG0825 (clinicaltrials.gov: NCT 00884741)
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BEV (10 mg/kg) is being introduced only after 3 weeks of
TMZ/RT, BEV is given every other week from the beginning of
irradiation in the Roche/Genentech sponsored AvaGlio trial
(clinicaltrials.gov: NCT 00943826). Both trials have completed
accrual of > 900 patients each; ﬁrst results are expected in 2013.
Until then, the available data does not justify the use of BEV in
the ﬁrst-line treatment of high-grade gliomas. Preclinical data
even suggest a potentially detrimental effect [33, 34]. The
optimal dose of BEV has never been investigated, and lower
doses may well result in a similar effect and less toxicity.
7. do all patients need pneumocystis prophylaxis?
Continuous TMZ administration has been associated with
profound lymphocytopenia, cellular immunosuppression and
opportunistic infections. The most common infectious agent
identiﬁed is Pneumocystis jirovecci (formerly known as
pneumocystis carini), but candida and listeria have also been
reported. The common use of corticosteroids further
exacerbates the immuno-deﬁcient state. Pneumocystis
pneumonia (PcP) prophylaxis with either pentamidine or
trimetoprim/sulfametoxazol or dapsone [35] has been
introduced after observation of 2 patients with PcP out of the
ﬁrst 15 treated with TMZ/RT [36]. Similar observations of
opportunistic infections were also reported elsewhere [37, 38].
In the randomized GBM trial, primary PcP prophylaxis was
mandatory, a recommendation that has also been included in
the ofﬁcial approval label for concomitant TMZ
chemoradiotherapy. In practice, prophylaxis may be
approached in different ways: Most commonly and considered
simple and safe, sulfa-drugs are prescribed to all patients (e.g.
Bactrim forte administered 3 times per week or dapsone
100 mg/day). However, these antibiotics are associated with a
risk of myelosuppression, that may be severe in conjunction
with chemotherapy. We prefer once monthly pentamidine
inhalations (Pentacarinat 300 mg q28d). With the appropriate
infrastructure, pentamidine inhalations are easy to perform,
well tolerated and do not add to the patients long list of oral
medications. Usually, two administrations are sufﬁcient, as
lymphocyte counts recover after the end of concomitant TMZ/
RT. Alternatively, one may consider surveillance of absolute
lymphocyte or CD4 counts. Prophylaxic treatment should be
introduced if the absolute lymphocytes drops below 500/mm3
(µl) or the CD4 below 200/mm3.
8. how to treat pure oligodendroglioma?
Oligodendroglioma have been recognized as a distinct
histological and molecularly deﬁned entity.
Oligodendrogliomas with LOH 1p/19q have been shown to
have a better outcome and better response to both
chemotherapy and to radiotherapy than oligodendrogliomas
without LOH 1p/19q [39–41]. Two large randomized trials by
EORTC and RTOG demonstrated median survival rates
beyond 7 years in patients with oligodendroglioma that carry a
translocation 1p/19q, compared with <3 years for patients with
absence of 1p/19q LOH [42, 43]. In a recent update of these
trials that enrolled patients over 10 years ago, a survival beneﬁt
for early PCV-chemotherapy (procarbazine, lomustine,
vincristine) has been suggested in the subgroup of patients
with an LOH 1p/19q (Cairncross et al., Proc ASCO 2012, van
den Bent et al. Proc ASCO 2012). These ﬁndings suggest that
early treatment with chemotherapy in addition to RT may
result in long-term control of LOH 1p/19q
oligodendrogliomas. Since the widespread availability and
acceptance of TMZ chemotherapy, this agent has largely
replaced the formerly popular PCV regimen. In a randomized
trial comparing directly PCV chemotherapy (224 patients)
with TMZ administered either over 5 days (200 mg/m2 for 5
days, 112 patients) or TMZ-21 (100 mg/m2 for 21 days) in
recurring high-grade gliomas, no signiﬁcant difference in
outcome between patients treated with PCV and TMZ was
found [27]. Similarly, a German study on anaplastic glioma
showed that outcome in patients treated with PCV or TMZ
was comparable [44]. More importantly, this same study also
demonstrated, that the sequence of treatment administration
(radiotherapy ﬁrst, chemotherapy at recurrence/progression or
chemotherapy as initial treatment and RT as salvage therapy)
did not substantially inﬂuence outcome [44]. For patients with
long survival time, the major objective is also to limit acute
and late treatment-related toxicity to a minimum. Given the
favorable toxicity proﬁle of TMZ compared with PCV and the
demonstration of efﬁcacy of TMZ in GBM patients, TMZ
nowadays is the preferred ﬁrst choice of chemotherapy.
While for a small tumor a 6-week course of fractionated
radiotherapy remains the treatment of choice, primary
chemotherapy with TMZ may be preferred in larger tumors
requiring an extensive radiation ﬁeld. Data on the concomitant
use of chemo- and radiotherapy in analogy to GBM are not
available.
9. what is the standard of care of anaplastic
astrocytoma?
In contrast to patients suffering from anaplastic
oligodendroglioma with LOH 1p/19q, the situation is very
different for patients that do not exhibit 1p/19q LOH. Those
patients have an expected median survival of only ∼2 years,
and almost invariably present with recurrence or progressive
disease [45]. For these patients, the historic ﬁrst-line standard
of care treatment has been RT, based on randomized data
when anaplastic glioma was treated within the same protocols
as GBM [46]. The NOA-04 trial included 274 patients and
showed that PFS and OS were similar regardless of whether
these patients were treated with RT as a ﬁrst line of treatment
followed by chemotherapy (PCV or TMZ) or by initial
chemotherapy followed by RT at recurrence [44]. It remains
however to be shown whether these patients may beneﬁt from
a combined ﬁrst-line treatment with a combination of RT and
TMZ. This is currently being evaluated in the phase III
CATNON trial, led by the EORTC, together with the German
NOA, the British Medical Research Council, the US RTOG,
NCCTG and Eastern Cooperative Oncology Group. This study
is investigating concomitant versus adjuvant TMZ
chemotherapy in a 2 × 2 design. Patients will be randomized to
either RT alone or the combination of TMZ/RT in a ﬁrst step
and then to either adjuvant TMZ (standard schedule, 150–200
mg/m2 daily for 5 days in a 28-day cycle) for 12 cycles (!) or
observation after RT alone. Currently, approximately one-third
of the planned 748 patients have been randomized.
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10. what is the role of radiosurgery in the
management of gliomas
Radiotherapy has been the mainstay for treatment of
malignant glioma for over 30 years [46, 47]. Although
improved survival has been demonstrated with RT doses of 60
Gy compared with 50 Gy [48], further attempts to dose
escalate by using accelerated or hyperfractionated schedules did
not translate into further improvement [49]. Local failure
remained the primary site of disease recurrence, and has been
seen with predominance in the areas of dose escalation [50–52].
To try to intensify radiotherapy dose, while keeping the
normal brain toxicity to acceptable levels, more focal methods,
such as stereotactic radiosurgery (SRS), have been added to
conventional fractionated external beam radiation therapy.
Radiosurgery is a technique that delivers a highly conformal
high dose to a precise target by using multiple focused beams
from multiple directions thanks to image guidance (stereotactic
system) in the three dimensions. It is able to minimize the
dose distribution to normal tissue. Several uncontrolled
retrospective and prospective studies suggested improved
survival when a SRS-boost was added to the conventional
radiotherapy in newly diagnosed gliomas [53–57]. These data
could, however, not be conﬁrmed by other studies [58]. In a
prospective multi-institutional, phase III randomized trial
(RTOG 93-05), SRS was added to standard external beam RT
and carmustine chemotherapy [59]. A total of 203 patients
with small (≤4 cm) supratentorial GBM were randomized to
receive or not a stereotactic boost to the contrast-enhancing
residual tumor for a dose of up to 24 Gy depending on the size
of the lesion. Median OS was 13.5 and 13.6 months in the SRS
and control groups, respectively (P = 0.57). Also, there were no
signiﬁcant differences in 2- and 3-year survival rates.
Subsequent efforts focused on accurate delineation of high-risk
regions that are more aggressive and may beneﬁt from
additional directed dose by magnetic resonance spectroscopy,
positron emission tomography using radiolabeled glucose as
well as methionine, ﬂuoro-ethyl tyrosine or similar tracers, and
magnetic resonance tumor perfusion imaging. In a phase II
trial using magnetic resonance spectroscopy-targeted SRS in
the treatment of patients with GBM, 35 patients underwent
surgical resection or biopsy, followed by SRS directed toward
areas of spectroscopically high biological activity within 2 cm
of the postoperative enhancing surgical bed. All patients
subsequently received conformal radiotherapy (60 Gy), 16 of
35 patients received concurrent TMZ. For these patients, the
median survival was a promising 20.8 months [60] but short of
a controlled study, no conclusions can be drawn.
At the time of GBM recurrence, retreatment with standard
RT often exposes the brain to an unacceptable risk of radiation
injury and necrosis. In this context, SRS may represent a
treatment option allowing to sparing surrounding brain
volume from re-irradiation and try to achieve control of
rapidly growing areas. Several studies pointed out the potential
utility of adjuvant SRS at recurrence, with median survival
time after SRS varying from 4.6 to 16 months [61–63]. The
value of these results is difﬁcult to establish given the fact that
patients are highly selected for very localized recurrences
amenable to radiosurgery.
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